I personally don’t see it as an issue. The risk can easily be mitigated via a clause similar to that of Acadia’s that Nueren can not target any symptoms covered by Trofinetide. The main issue to me is to agree on the value as pointed out by Jon at the AGM.
I personally don’t see it as an issue. The risk can easily be...
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.61 |
Change
0.395(2.60%) |
Mkt cap ! $1.994B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $4.295M | 275.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 1458 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.61 | 2130 | 36 |
View Market Depth
| Last trade - 15.00pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |